eligibility_summary
Inclusion: Ovarian clear cell carcinoma (≥70% if mixed), measurable disease (RECIST 1.1), HER2 IHC ≥1+, ≤2 prior chemo lines (incl. progression during/after platinum, recurrent platinum‑sens/resist), prior bevacizumab allowed, adequate marrow/organ function (WBC ≥3.0, ANC ≥1.5, PLT ≥100, Hgb ≥80, AST/ALT ≤2.5×ULN, TBil ≤1.5×, Cr ≤1.5×), ECOG 0–1, consent. Exclusion: prior immunotherapy, other cancers <5y (except skin/thyroid), OS ≤12 wks, taxane allergy, contraindications to immunotherapy/bev, on other trials, unstable conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: Disitamab vedotin (RC48), a HER2-targeted antibody–drug conjugate carrying the microtubule toxin MMAE, AK104 (cadonilimab), a bispecific monoclonal antibody that binds PD-1 and CTLA-4, Bevacizumab, an anti-VEGF-A monoclonal antibody. Mechanisms of action: RC48 binds HER2 on tumor cells, is internalized, and releases MMAE to disrupt microtubules and induce apoptosis (with potential bystander effect). AK104 concurrently blocks PD-1 and CTLA-4 to reinvigorate effector T cells and diminish Treg-mediated suppression. Bevacizumab neutralizes VEGF-A to inhibit angiogenesis and normalize tumor vasculature, improving immune infiltration. Targets/pathways: HER2/ERBB2 on OCCC cells, microtubule cytoskeleton, PD-1 and CTLA-4 checkpoints on T cells, VEGF/VEGFR signaling on endothelial cells and the tumor microenvironment. Population: recurrent/persistent OCCC, HER2 IHC ≥1+.